Summary
Sera of 34 patients with progressive systemic sclerosis and of 11 patients with polymyositis/dermatomyositis (PM/DM) were analyzed by the immunoblotting technique for the presence of marker antibodies. The presence of anti-centromere, anti-Topoisomerase-I (anti-Topo-I) and anti-Jo-1 antibodies was found to be highly specific for the CREST syndrome, diffuse scleroderma and PM/DM, respectively, but only of limited sensitivity (78, 44 and 45%, respectively). Anti-Topo-I positive diffuse scleroderma patients had a more severe disease (digital pitting scars and renal insufficency) than anti-Topo-I negative diffuse scleroderma patients. Anti-Jo-1 was associated with interstitial lung disease. Longitudinal studies showed a constant antibody pattern. Our results confirm the clinical usefulness of these marker antibodies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tan, E.M. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982, 33, 167–240.
Moroi, Y., Peebles, C., Fritzler, M.J., Steigerwald, J., Tan, E.M. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci USA 1980, 77, 1627–1631.
Tan, E.M., Rodnan, G.P., Garcia, I., Moroi, Y., Fritzler, M.J., Peebles. Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 1980, 23, 617–625.
Douvas, A.S., Achten, M., Tan, E.M. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979, 254, 10514–10522.
Fritzler, M.J., Kinsella, T.D., Garbutt, E. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 1980, 69, 520–526.
Nishikai, M., Reichlin, M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Arthritis Rheum 1980, 23, 881–888.
Guldner, H.H., Lakomek, H.J., Bautz, F.A. Human anti-centromere sera recognise a 19.5 kD nonhistone chromosomal protein from HeLa cells. Clin Exp Immunol 1985, 59, 457–466.
Van Venrooij, W.J., Stapel, S.O., Houben, H., Habets, W.J., Kallenberg, C.G.M., Penner, E., van de Putte, L.B.A. Scl-86, a marker antigen for diffuse scleroderma. J Clin Invest 1985, 75, 1053–1060.
Shero, J.H., Bordwell, B., Rothfield, N.F., Earnshaw, W.C. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986, 231, 737–40.
Maul, G.G., French, B.T., van Venrooij, W.J., Jimenez, S.A. Topoisomerase-I identified by scleroderma 70 antisera: enrichment of topoisomerase-I at the centromere in mouse mitotic cells before anaphase. Proc Natl Acad Sci USA 1986, 83, 5145–5149.
Mathews, M.B., Bernstein, R.M. Myositis autoantibody inhibits histidyl-t RNA synthetase: a model for autoimmunity. Nature 1983, 304, 177–183.
Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23, 581–590.
Bohan, A., James, J.B., Bowman, R.L., Pearson, C.M. A computerassisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977, 56, 255–286.
Habets, W.J., de Rooij, D.J., Hoet, M.H., van de Putte, L.B., van Venrooij, W.J. Quantitation of anti-RNP and anti-Sm antibodies in MCTD and SLE patients by immunoblotting. Clin Exp Immunol 1985, 59, 457–466.
De Rooij, D.J., van de Putte, L.B., Habets, W.J., Verbeek, A.L., van Venrooij, W.J. The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic diseases. Scand J Rheumatol, 1988, 17, 353–364.
Yoshida, S., Akizuki, M., Mimori, T., Yamagata, H., Inada, S., Homma, M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. Arthritis Rheum 1983, 26, 604–611.
Rufatti, A., Calligaro, A., Ferri, C., Bombardieri, S., Gambari, P.F., Todesco, S. Association of anticentromere and anti-Scl 70 antibodies in scleroderma: report of two cases. J Clin Lab Immunol 1985, 16, 227–229.
Weiner, E.S., Earnshaw, W.C., Senécal, J.L., Bordwell, B., Johnson, P., Rothfield, N.F. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. Arthritis Rheum 1988, 31, 378–385.
Steen, V.D., Powell, D.L., Medsger, T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988, 31, 196–203.
Cattogio, L.J., Bernstein, R.M., Black, C.M., Hughes, G.R.V., Maddison, P.J. Serologic markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983, 42, 23–27.
Meurer, M., Scharf, A., Luderschmidt, Ch., Braun-Falco, O. Zentromerantikörper und Antikörper gegen Scl-70-Nucleoprotein bei progressiver systemischer Sklerodermie. Dtsch Med Wochenschr 1985, 110, 8–14.
McCarty, G.A., Rice, J.R., Bembe, M.L., Barada, R.A. Anricentromere antibody: clinical correlations and association with favourable prognosis in patients with scleroderma variants. Arthritis Rheum 1983, 26, 1–7.
Tramposch, H.D., Smith, C.D., Senécal, J.L., Rothfield, N. A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984, 27, 121–124.
Fudman, E.J., Schnitzer, T.J. Clinical and biochemical characteristics of autoantibody systems in polymyositis and dermatomyositis. Semin Arthritis Rheum 1986, 15, 255–260.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
De Rooij, D.J., Van De Putte, L.B.A., Habets, W.J. et al. Marker antibodies in scleroderma and polymyositis: Clinical associations. Clin Rheumatol 8, 231–237 (1989). https://doi.org/10.1007/BF02030079
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02030079